106 related articles for article (PubMed ID: 15382198)
1. 1-(2-pyrimidinyl)-piperazine, a buspirone metabolite, modulates bladder function in the anesthetized rat.
Myers RA; Plym MJ; Signor LJ; Lodge NJ
Neurourol Urodyn; 2004; 23(7):709-15. PubMed ID: 15382198
[TBL] [Abstract][Full Text] [Related]
2. Effects of ATP-sensitive K+ channel openers and tolterodine on involuntary bladder contractions in a pig model of partial bladder outlet obstruction.
Fey TA; Gopalakrishnan M; Strake JG; King LL; Brioni JD; Sullivan JP; Coghlan MJ; Brune ME
Neurourol Urodyn; 2003; 22(2):147-55. PubMed ID: 12579633
[TBL] [Abstract][Full Text] [Related]
3. Urodynamic effects of oxybutynin and tolterodine in conscious and anesthetized rats under different cystometrographic conditions.
Angelico P; Velasco C; Guarneri L; Sironi G; Leonardi A; Testa R
BMC Pharmacol; 2005 Oct; 5():14. PubMed ID: 16216132
[TBL] [Abstract][Full Text] [Related]
4. Tolterodine and its active 5-hydroxymethyl metabolite: pure muscarinic receptor antagonists.
Nilvebrant L
Pharmacol Toxicol; 2002 May; 90(5):260-7. PubMed ID: 12076307
[TBL] [Abstract][Full Text] [Related]
5. The effects of a type 4 phosphodiesterase inhibitor and the muscarinic cholinergic antagonist tolterodine tartrate on detrusor overactivity in female rats with bladder outlet obstruction.
Kaiho Y; Nishiguchi J; Kwon DD; Chancellor MB; Arai Y; Snyder PB; Yoshimura N
BJU Int; 2008 Mar; 101(5):615-20. PubMed ID: 18070178
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological effects of propiverine and its active metabolite, M-1, on isolated human urinary bladder smooth muscle, and on bladder contraction in rats.
Sugiyama Y; Yoshida M; Masunaga K; Satoji Y; Maeda Y; Nagata T; Inadome A; Ueda S
Int J Urol; 2008 Jan; 15(1):76-81. PubMed ID: 18184179
[TBL] [Abstract][Full Text] [Related]
7. Effects on bladder function of combining elocalcitol and tolterodine in rats with outflow obstruction.
Streng T; Andersson KE; Hedlund P; Gratzke C; Baroni E; D'Ambrosio D; Benigni F
BJU Int; 2012 Jul; 110(2 Pt 2):E125-31. PubMed ID: 22288904
[TBL] [Abstract][Full Text] [Related]
8. Antimuscarinic agents exhibit local inhibitory effects on muscarinic receptors in bladder-afferent pathways.
Kim Y; Yoshimura N; Masuda H; de Miguel F; Chancellor MB
Urology; 2005 Feb; 65(2):238-42. PubMed ID: 15708029
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the effects of novel antimuscarinic drugs on human detrusor smooth muscle.
Yono M; Yoshida M; Takahashi W; Inadome A; Ueda S
BJU Int; 2000 Oct; 86(6):719-25. PubMed ID: 11069384
[TBL] [Abstract][Full Text] [Related]
10. Effects of ritobegron (KUC-7483), a novel β3-adrenoceptor agonist, on both rat bladder function following partial bladder outlet obstruction and on rat salivary secretion: a comparison with the effects of tolterodine.
Maruyama I; Yonekubo S; Tatemichi S; Maruyama K; Hoyano Y; Yamazaki Y; Kusama H
J Smooth Muscle Res; 2012; 48(5-6):115-24. PubMed ID: 23538508
[TBL] [Abstract][Full Text] [Related]
11. Modulation of non-voiding activity by the muscarinergic antagonist tolterodine and the β(3)-adrenoceptor agonist mirabegron in conscious rats with partial outflow obstruction.
Gillespie JI; Palea S; Guilloteau V; Guerard M; Lluel P; Korstanje C
BJU Int; 2012 Jul; 110(2 Pt 2):E132-42. PubMed ID: 22734512
[TBL] [Abstract][Full Text] [Related]
12. Effect of mirabegron, a novel β3-adrenoceptor agonist, on bladder function during storage phase in rats.
Hatanaka T; Ukai M; Watanabe M; Someya A; Ohtake A; Suzuki M; Ueshima K; Sato S; Kaku S
Naunyn Schmiedebergs Arch Pharmacol; 2013 Jan; 386(1):71-8. PubMed ID: 23224420
[TBL] [Abstract][Full Text] [Related]
13. Antimuscarinic potency and bladder selectivity of PNU-200577, a major metabolite of tolterodine.
Nilvebrant L; Gillberg PG; Sparf B
Pharmacol Toxicol; 1997 Oct; 81(4):169-72. PubMed ID: 9353847
[TBL] [Abstract][Full Text] [Related]
14. Effects of antimuscarinics on voiding function after cerebral infarction in a rat model of overactive bladder.
Yusup A; Akino H; Miwa Y; Oyama N; Aoki Y; Ito H; Tanase K; Matsuta Y; Nakai M; Yokoyama O
Eur J Pharmacol; 2007 Dec; 577(1-3):143-9. PubMed ID: 17904547
[TBL] [Abstract][Full Text] [Related]
15. Effects of TAK-637, a tachykinin receptor antagonist, on the micturition reflex in guinea pigs.
Doi T; Kamo I; Imai S; Okanishi S; Ikeura Y; Natsugari H
Eur J Pharmacol; 2000 May; 395(3):241-6. PubMed ID: 10812055
[TBL] [Abstract][Full Text] [Related]
16. Urodynamic and other effects of tolterodine: a novel antimuscarinic drug for the treatment of detrusor overactivity.
Stahl MM; Ekström B; Sparf B; Mattiasson A; Andersson KE
Neurourol Urodyn; 1995; 14(6):647-55. PubMed ID: 8750383
[TBL] [Abstract][Full Text] [Related]
17. In vivo evaluation of the potency and bladder-vascular selectivity of the ATP-sensitive potassium channel openers (-)-cromakalim, ZD6169 and WAY-133537 in rats.
Fabiyi AC; Gopalakrishnan M; Lynch JJ; Brioni JD; Coghlan MJ; Brune ME
BJU Int; 2003 Feb; 91(3):284-90. PubMed ID: 12581020
[TBL] [Abstract][Full Text] [Related]
18. Effects of tolterodine on afferent neurotransmission in normal and resiniferatoxin treated conscious rats.
Hedlund P; Streng T; Lee T; Andersson KE
J Urol; 2007 Jul; 178(1):326-31. PubMed ID: 17507042
[TBL] [Abstract][Full Text] [Related]
19. Comparative analysis of the effects of antimuscarinic agents on bladder functions in both nonhuman primates and rodents.
Nagabukuro H; Villa KL; Wickham LA; Kulick AA; Gichuru L; Donnelly MJ; Voronin GO; Pereira T; Tong X; Nichols A; Alves SE; O'Neill GP; Johnson CV; Hickey EJ
J Pharmacol Exp Ther; 2011 Jul; 338(1):220-7. PubMed ID: 21459965
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological and genetic analysis of mechanisms underlying detrusor overactivity in rats.
Yokoyama O
Neurourol Urodyn; 2010; 29(1):107-11. PubMed ID: 20025014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
